Testing effectiveness (Phase 2)Study completedNCT01827371
What this trial is testing
Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®
Who this might be right for
Smallpox
National Institute of Allergy and Infectious Diseases (NIAID) 435